Symbols / CLDI $0.22 -5.68% Calidi Biotherapeutics, Inc.

Healthcare • Biotechnology • United States • ASE
CLDI Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Eric E. Poma Ph.D.
Exch · Country ASE · United States
Market Cap 2.44M
Enterprise Value -561.76K
Income -25.58M
Sales —
FCF (ttm) -11.85M
Book/sh 0.51
Cash/sh 0.51
Employees 29
Insider 10d —
IPO Nov 01, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.25
PEG —
P/S —
P/B 0.44
P/C —
EV/EBITDA 0.03
EV/Sales —
Quick Ratio 1.42
Current Ratio 1.59
Debt/Eq 68.21
LT Debt/Eq —
EPS (ttm) -5.95
EPS next Y -0.90
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-13
Earnings (prior) 2025-11-13
ROA -109.81%
ROE -7.01%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 10.90M
Shs Float 10.58M
Insider Own 3.31%
Instit Own 4.31%
Short Float 2.60%
Short Ratio 0.33
Short Interest 275.08K
52W High 19.20
vs 52W High -98.83%
52W Low 0.21
vs 52W Low 7.18%
Beta 1.42
Impl. Vol. —
Rel Volume 43.81
Avg Volume 3.38M
Volume 148.16M
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $0.24
Price $0.22
Change -5.68%
About

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors. It also offers oncolytic virus platforms, such as NeuroNova and SuperNova. Calidi Biotherapeutics, Inc. was founded in 2014 and is headquartered in San Diego, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.22
Latest analyst target
3. DCF / Fair value
$-19.58
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.22
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2024-06-27 init Ladenburg Thalmann — → Buy $1
2024-05-15 main Baird Outperform → Outperform $2
2024-03-21 main Baird Outperform → Outperform $5
2024-03-21 main HC Wainwright & Co. Buy → Buy $2
2023-11-22 init HC Wainwright & Co. — → Buy $11
2023-10-09 init Baird — → Outperform $9
News
RSS: Latest CLDI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2025-12-12 CAMAISA ALLAN Director — 850 $1.46 $1,237
2025-08-21 POMA ERIC E. PH.D. Chief Executive Officer — 25,000 $2.00 $50,000
2025-08-21 SCHOENECK JAMES A Director — 75,000 $2.00 $150,000
2025-08-21 JACKSON ANDREW C Chief Financial Officer — 2,500 $2.00 $5,000
2025-08-21 LEFTWICH SCOTT Director — 125,000 $2.00 $250,000
2024-12-31 STEWART ALAN R Director — 12,771 — —
2024-12-31 LEFTWICH SCOTT Director — 11,684 — —
2024-12-17 CAMAISA ALLAN Chief Executive Officer — 10,000 $1.62 $16,200
2024-09-26 CAMAISA ALLAN Chief Executive Officer — 70,155 $1.15 $80,678
2024-06-28 SCHOENECK JAMES A Director — 79,687 — —
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
-100.00%
0.04
Operating Revenue
0.00
0.00
0.00
-100.00%
0.04
Cost Of Revenue
—
—
0.00
-100.00%
0.01
Reconciled Cost Of Revenue
—
—
0.00
-100.00%
0.01
Gross Profit
—
—
0.00
-100.00%
0.03
Operating Expense
20.19
-6.51%
21.59
-17.28%
26.11
+12.73%
23.16
Research And Development
9.74
+9.68%
8.88
-31.75%
13.01
+79.25%
7.26
Selling General And Administration
10.50
-18.57%
12.90
-19.31%
15.98
+0.52%
15.90
General And Administrative Expense
10.50
-18.57%
12.90
-19.31%
15.98
+0.52%
15.90
Other Gand A
10.50
-18.57%
12.90
-19.31%
15.98
+0.52%
15.90
Other Operating Expenses
-0.05
+72.38%
-0.18
+93.73%
-2.88
—
Total Expenses
20.19
-6.51%
21.59
-17.28%
26.11
+12.66%
23.17
Operating Income
-20.19
+6.51%
-21.59
+17.28%
-26.11
-12.88%
-23.13
Total Operating Income As Reported
-20.24
+7.05%
-21.78
+24.89%
-28.99
-25.35%
-23.13
EBITDA
-18.19
+7.79%
-19.73
+26.60%
-26.88
-7.48%
-25.00
Normalized EBITDA
-18.44
+8.05%
-20.05
+27.30%
-27.58
-20.55%
-22.88
Reconciled Depreciation
1.65
+7.56%
1.53
+22.21%
1.26
+396.44%
0.25
EBIT
-19.84
+6.68%
-21.26
+24.42%
-28.13
-11.37%
-25.26
Total Unusual Items
0.25
-24.07%
0.32
-54.17%
0.71
+133.27%
-2.12
Total Unusual Items Excluding Goodwill
0.25
-24.07%
0.32
-54.17%
0.71
+133.27%
-2.12
Special Income Charges
0.24
0.00
+100.00%
-0.47
0.00
Other Special Charges
—
—
0.47
—
Net Income
-19.91
+10.10%
-22.14
+24.21%
-29.22
-14.90%
-25.43
Pretax Income
-20.05
+9.67%
-22.20
+23.99%
-29.20
-14.89%
-25.42
Net Non Operating Interest Income Expense
-0.21
+77.81%
-0.93
+75.11%
-3.75
-2272.78%
-0.16
Interest Expense Non Operating
0.21
-77.81%
0.93
-12.72%
1.07
+576.58%
0.16
Net Interest Income
-0.21
+77.81%
-0.93
+75.11%
-3.75
-2272.78%
-0.16
Interest Expense
0.21
-77.81%
0.93
-12.72%
1.07
+576.58%
0.16
Other Income Expense
0.35
+4.80%
0.33
-49.24%
0.66
+130.80%
-2.13
Other Non Operating Income Expenses
0.10
+1044.44%
0.01
+117.65%
-0.05
-920.00%
-0.01
Gain On Sale Of Security
0.00
-99.38%
0.32
-72.50%
1.18
+155.44%
-2.12
Gain On Sale Of Business
0.24
0.00
—
—
Tax Provision
0.01
+7.14%
0.01
-12.50%
0.02
+45.45%
0.01
Tax Rate For Calcs
0.00
-100.00%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
-100.00%
0.07
-54.17%
0.15
+133.27%
-0.45
Net Income Including Noncontrolling Interests
-20.06
+9.66%
-22.21
+23.98%
-29.22
-14.90%
-25.43
Net Income From Continuing Operation Net Minority Interest
-19.91
+10.10%
-22.14
+24.21%
-29.22
-14.90%
-25.43
Net Income From Continuing And Discontinued Operation
-19.91
+10.10%
-22.14
+24.21%
-29.22
-14.90%
-25.43
Net Income Continuous Operations
-20.06
+9.66%
-22.21
+23.98%
-29.22
-14.90%
-25.43
Minority Interests
0.16
+137.88%
0.07
0.00
—
Normalized Income
-20.15
+10.03%
-22.40
+24.77%
-29.77
-25.38%
-23.75
Net Income Common Stockholders
-25.58
-7.41%
-23.81
+18.49%
-29.22
-14.90%
-25.43
Otherunder Preferred Stock Dividend
5.67
+239.50%
1.67
0.00
—
Diluted EPS
-5.95
+83.33%
-35.70
+82.83%
-207.96
-144.72%
-84.98
Basic EPS
-5.95
+83.33%
-35.70
+82.83%
-207.96
-144.72%
-84.98
Basic Average Shares
4.30
+544.98%
0.67
+374.74%
0.14
-53.05%
0.30
Diluted Average Shares
4.30
+544.98%
0.67
+374.74%
0.14
-53.05%
0.30
Diluted NI Availto Com Stockholders
-25.58
-7.41%
-23.81
+18.49%
-29.22
-14.90%
-25.43
Total Other Finance Cost
—
—
2.68
—
Line Item Trend 2023-12-31
Total Assets
10.02
Current Assets
4.30
Cash Cash Equivalents And Short Term Investments
1.95
Cash And Cash Equivalents
1.95
Cash Financial
1.95
Receivables
1.36
Other Receivables
1.36
Prepaid Assets
0.77
Other Current Assets
0.23
Total Non Current Assets
5.72
Net PPE
5.34
Gross PPE
6.34
Accumulated Depreciation
-0.99
Machinery Furniture Equipment
2.26
Other Properties
4.07
Other Non Current Assets
0.37
Total Liabilities Net Minority Interest
18.25
Current Liabilities
10.23
Payables And Accrued Expenses
8.31
Payables
2.88
Accounts Payable
2.80
Current Accrued Expenses
5.43
Current Debt And Capital Lease Obligation
1.92
Current Debt
0.81
Other Current Borrowings
0.81
Current Capital Lease Obligation
1.12
Other Current Liabilities
—
Total Non Current Liabilities Net Minority Interest
8.02
Long Term Debt And Capital Lease Obligation
5.31
Long Term Debt
2.06
Long Term Capital Lease Obligation
3.25
Tradeand Other Payables Non Current
0.00
Other Non Current Liabilities
1.50
Preferred Securities Outside Stock Equity
0.00
Stockholders Equity
-8.23
Common Stock Equity
-8.23
Capital Stock
0.00
Common Stock
0.00
Share Issued
0.30
Ordinary Shares Number
0.30
Treasury Shares Number
0.00
Additional Paid In Capital
91.38
Retained Earnings
-99.57
Gains Losses Not Affecting Retained Earnings
-0.05
Minority Interest
0.00
Other Equity Adjustments
-0.05
Total Equity Gross Minority Interest
-8.23
Total Capitalization
-6.17
Working Capital
-5.93
Invested Capital
-5.37
Total Debt
7.24
Net Debt
0.92
Capital Lease Obligations
4.37
Net Tangible Assets
-8.23
Tangible Book Value
-8.23
Current Notes Payable
0.53
Derivative Product Liabilities
0.67
Dueto Related Parties Current
0.08
Dueto Related Parties Non Current
0.54
Financial Assets
0.23
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-21.29
-8.12%
-19.69
+27.01%
-26.98
-104.20%
-13.21
Cash Flow From Continuing Operating Activities
-21.29
-8.12%
-19.69
+27.01%
-26.98
-104.20%
-13.21
Net Income From Continuing Operations
-20.06
+9.66%
-22.21
+23.98%
-29.22
-14.90%
-25.43
Depreciation Amortization Depletion
1.65
+7.56%
1.53
+22.21%
1.26
+396.44%
0.25
Depreciation
—
1.53
+22.21%
1.26
+396.44%
0.25
Depreciation And Amortization
1.65
+7.56%
1.53
+22.21%
1.26
+396.44%
0.25
Other Non Cash Items
-0.00
+99.28%
-0.28
-114.43%
1.93
-13.97%
2.25
Stock Based Compensation
2.11
-28.71%
2.96
-38.51%
4.81
-21.72%
6.14
Operating Gains Losses
-0.24
—
0.48
—
Unrealized Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
—
0.00
-100.00%
0.01
0.00
Change In Working Capital
-4.74
-179.33%
-1.70
+72.80%
-6.24
-274.89%
3.57
Change In Prepaid Assets
-0.04
-102.33%
1.80
+181.16%
-2.22
-1405.29%
0.17
Change In Payables And Accrued Expense
-3.32
-33.80%
-2.48
+49.30%
-4.89
-244.01%
3.40
Change In Accrued Expense
-1.99
-7.50%
-1.85
-245.41%
1.27
-28.17%
1.77
Change In Payable
-1.33
-111.46%
-0.63
+89.82%
-6.17
-479.93%
1.62
Change In Account Payable
-1.33
-111.46%
-0.63
+89.82%
-6.17
-479.93%
1.62
Change In Other Current Liabilities
-1.38
-35.69%
-1.02
-216.63%
0.87
0.00
Investing Cash Flow
-0.17
-962.50%
-0.02
+96.65%
-0.48
+3.24%
-0.49
Cash Flow From Continuing Investing Activities
-0.17
-962.50%
-0.02
+96.65%
-0.48
+3.24%
-0.49
Net PPE Purchase And Sale
-0.12
-650.00%
-0.02
+97.26%
-0.58
-36.68%
-0.43
Purchase Of PPE
-0.12
-650.00%
-0.02
+97.26%
-0.58
-36.68%
-0.43
Capital Expenditure
-0.12
-650.00%
-0.02
+97.26%
-0.58
-36.68%
-0.43
Net Business Purchase And Sale
-0.05
0.00
-100.00%
0.01
0.00
Purchase Of Business
-0.05
0.00
—
—
Gain Loss On Sale Of Business
-0.24
0.00
—
—
Net Other Investing Changes
—
—
0.10
+248.48%
-0.07
Financing Cash Flow
17.46
-36.20%
27.36
-5.78%
29.04
+140.29%
12.09
Cash Flow From Continuing Financing Activities
17.46
-36.20%
27.36
-5.78%
29.04
+140.29%
12.09
Net Issuance Payments Of Debt
-2.49
-229.82%
1.92
+113.35%
0.90
-34.90%
1.38
Issuance Of Debt
0.00
-100.00%
3.80
+16.92%
3.25
+116.67%
1.50
Repayment Of Debt
-2.49
-32.31%
-1.88
+19.95%
-2.35
-1875.63%
-0.12
Long Term Debt Issuance
0.00
-100.00%
3.60
0.00
—
Long Term Debt Payments
-2.29
-21.68%
-1.88
+19.95%
-2.35
-1875.63%
-0.12
Net Long Term Debt Issuance
-2.29
-233.29%
1.72
+173.08%
-2.35
-1875.63%
-0.12
Short Term Debt Issuance
0.00
-100.00%
0.20
-93.85%
3.25
+116.67%
1.50
Short Term Debt Payments
-0.20
0.00
+100.00%
-0.30
0.00
Net Short Term Debt Issuance
-0.20
-200.00%
0.20
-93.85%
3.25
+116.67%
1.50
Net Common Stock Issuance
16.65
-7.81%
18.07
+553.82%
2.76
0.00
Repurchase Of Capital Stock
—
—
—
—
Proceeds From Stock Option Exercised
4.14
-40.37%
6.95
+2371.53%
0.28
+146.49%
0.11
Net Other Financing Charges
-0.85
-293.59%
0.44
-27.65%
0.60
-94.30%
10.59
Changes In Cash
-4.00
-152.31%
7.66
+383.58%
1.58
+197.66%
-1.62
Effect Of Exchange Rate Changes
0.01
+207.69%
-0.01
-116.67%
-0.01
+76.92%
-0.03
Beginning Cash Position
9.81
+352.65%
2.17
+267.29%
0.59
-73.63%
2.24
End Cash Position
5.82
-40.68%
9.81
+352.65%
2.17
+267.29%
0.59
Free Cash Flow
-21.41
-8.64%
-19.71
+28.50%
-27.57
-102.08%
-13.64
Interest Paid Supplemental Data
1.26
+803.57%
0.14
-65.35%
0.40
+1054.29%
0.04
Income Tax Paid Supplemental Data
0.02
+21.43%
0.01
+27.27%
0.01
+0.00%
0.01
Common Stock Issuance
16.65
-7.81%
18.07
+553.82%
2.76
0.00
Issuance Of Capital Stock
16.65
-7.81%
18.07
-33.73%
27.26
0.00
Net Preferred Stock Issuance
—
0.00
-100.00%
24.50
0.00
Preferred Stock Issuance
—
0.00
-100.00%
24.50
0.00
Preferred Stock Payments
—
—
—
—
Sale Of Business
—
0.00
-100.00%
0.01
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category